Whitesnake released their hit song “Here I Go Again” back in 1982. Fast forward to 2025, and we are once again faced with another blood pressure medication recall, this time due to elevated levels of potentially cancer-causing chemicals. Teva Pharmaceuticals USA Inc. is recalling 580,844 bottles of its prazosin hydrochloride capsules, as reported by the Food and Drug Administration enforcement report.
This is not the first time we have seen such recalls in recent years. In fact, there have been multiple instances of blood pressure medication recalls for cancer concerns dating back to 2018. The impurity of concern in this particular recall is a N-nitroso Prazosin impurity C, a compound classified as a potential carcinogen according to the 15th Report on Carcinogens from the National Toxicology Program.
Prazosin hydrochloride is a commonly prescribed medication used to treat high blood pressure, benign prostatic hyperplasia, PTSD-associated nightmares, and the Raynaud phenomenon. The medication works by blocking alpha-1 adrenergic receptors in the smooth muscle of blood vessels, leading to vasodilation and lowered blood pressure.
If you are currently taking prazosin hydrochloride, it is important to determine whether your medication is part of the recall. The affected capsules come in three different doses: 1, 2, and 5 mg. Check the manufacturer, National Drug Code (NDC), and expiration date of your medication against the list provided by the FDA.
While the FDA has classified this recall as “Class II,” indicating potential for temporary or reversible adverse health effects, it is crucial to take precautions. Exposure to carcinogens over time can increase the risk of developing cancer. Therefore, it is recommended to stop taking the recalled medication, return or dispose of it properly, and seek alternative treatment options.
The frequency of medication recalls due to impurities raises concerns about drug safety regulations and oversight. With nearly half of adults in the U.S. dealing with high blood pressure, ensuring the safety and efficacy of medications is paramount. It is essential for regulatory bodies like the FDA to address these issues and implement measures to prevent such incidents in the future.
